Advances in foamy virus vector technology and disease correction could speed the path to clinical application

Molecular Therapy

Volumn 20, Issue 6, 2012, Pages 1105-1107

  Verhoeyen, Els ^a,b,c  

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR; VIRUS VECTOR;

BETA THALASSEMIA; DNA INTEGRATION; EMBRYONIC STEM CELL; FANCONI ANEMIA; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SILENCING; GENE TRANSFER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NONHUMAN; NOTE; PSEUDOTYPING; SPUMA VIRUS; TRANSCRIPTION INITIATION SITE; TRANSGENE; VIRAL GENE THERAPY; WISKOTT ALDRICH SYNDROME;

HUMAN SPUMARETROVIRUS;

EID: 84861872367     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.97     Document Type: Note

References (25)

1. Nasimuzzaman, Md and Persons, DA (2012). Cell membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells. Mol Ther 20: 1158-1166.
2. Ho, Y-P, Schnabel, V, Swiersy, A, Stirnnagel, K and Lindemann, D (2012). A small-molecule-controlled system for efficient pseudotyping of prototype foamy virus vectors. Mol Ther 20: 1167-1176.
3. Uchiyama, T, Adriani, M, Jagadeesh, GJ, Paine, A and Candotti, F (2012). Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome. Mol Ther 20: 1270-1279.
4. Boztug, K, Schmidt, M, Schwarzer, A, Banerjee, PP, Díez, IA, Dewey, RA et al. (2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 363: 1918-1927.
5. Switzer, WM, Salemi, M, Shanmugam, V, Gao, F, Cong, M, Kuiken, C et al. (2005). Ancient co-speciation of simian foamy viruses and primates. Nature 434: 376-380. (Pubitemid 40469179)
6. Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467: 318-322.
7. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
8. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Kowhl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
9. Schroder, AR, Shinn, P, Chen, H, Berry, C, Ecker, JR and Bushman, F (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529. (Pubitemid 35232295)
10. Hematti, P, Hong, B-K, Ferguson, C, Adler, R, Hanawa, H, Sellers, S et al. (2004). Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2: e423.
11. Bauer, TR, Jr, Allen, JM, Hai, M, Tuschong, LM, Khan, IF, Olson, EM et al. (2008). Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med 14: 93-97.
12. Trobridge, GD, Miller, DG, Jacobs, MA, Allen, JM, Kiem, H-P, Kaul, R et al. (2006). Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA 103: 1498-1503. (Pubitemid 43191194)
13. Hill, CL, Bieniasz, PD and McClure, MO (1999). Properties of human foamy virus relevant to its development as a vector for gene therapy. J Gen Virol 80: 2003-2009. (Pubitemid 29389136)
14. Manel, N, Kim, FJ, Kinet, S, Taylor, N, Sitbon, M and Battini, JL (2003). The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 115: 449-459. (Pubitemid 37456807)
15. Pietschmann, T, Heinkelein, M, Heldmann, M, Zentgraf, H, Rethwilm, A and Lindemann, D (1999). Foamy virus capsids require the cognate envelope protein for particle export. J Virol 73: 2613-2621. (Pubitemid 29135645)
16. Rothenaigner, I, Kramer, S, Meggendorfer, M, Rethwilm, A and Brack-Werner, R (2009). Transduction of human neural progenitor cells with foamy virus vectors for differentiation-dependent gene expression. Gene Ther 16: 349-358.
17. Gharwan, H, Hirata, RK, Wang, P, Richard, RE, Wang, L, Olson, E et al. (2007). Transduction of human embryonic stem cells by foamy virus vectors. Mol Ther 15: 1827-1833. (Pubitemid 47434190)
18. Leurs, C, Jansen, M, Pollok, KE, Heinkelein, M, Schmidt, M, Wissler, M et al. (2003). Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34+ cord blood cells. Hum Gene Ther 14: 509-519. (Pubitemid 36442706)
19. Kiem, HP, Allen, J, Trobridge, G, Olson, E, Keyser, K, Peterson, L et al. (2007). Foamy virus-mediated gene transfer to canine repopulating cells. Blood 109: 65-70. (Pubitemid 46053045)
20. Si, Y, Pulliam, AC, Linka, Y, Ciccone, S, Leurs, C, Yuan, J et al. (2008). Overnight transduction with foamyviral vectors restores the long-term repopulating activity of Fancc-/- stem cells. Blood 112: 4458-4465.
21. Lehmann-Che, J, Renault, N, Giron, ML, Roingeard, P, Clave, E, Tobaly-Tapiero, J et al. (2007). Centrosomal latency of incoming foamy viruses in resting cells. PLoS Pathog 3: e74.
22. Morianos, I, Siapati, EK, Pongas, G and Vassilopoulos, G (2012). Comparative analysis of FV vectors with human alpha- or beta-globin gene regulatory elements for the correction of beta-thalassemia. Gene Ther 19: 303-311.
23. Chatziandreou, I, Siapati, EK and Vassilopoulos, G (2011). Genetic correction of X-linked chronic granulomatous disease with novel foamy virus vectors. Exp Hematol 39: 643-652.
24. Frecha, C, Costa, C, Lévy, C, Nègre, D, Russell, SJ, Maisner, A et al. (2009). Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 114: 3173-3180.
25. Funke, S, Maisner, A, Mühlebach, MD, Koehl, U, Grez, M, Cattaneo, R et al. (2008). Targeted cell entry of lentiviral vectors. Mol Ther 16: 1427-1436.